MB circumscribed breast masses often benign

This article originally appeared here.
Share this content:
Multiple Bilateral Circumscribed Breast Masses Usually Benign
Multiple Bilateral Circumscribed Breast Masses Usually Benign

(HealthDay News) -- Multiple bilateral (MB) circumscribed breast masses detected with ultrasound screening are almost always benign, according to research published in the September issue of Radiology.

Wendie A. Berg, M.D., Ph.D., from the American College of Radiology Imaging Network in Philadelphia, and colleagues analyzed data from 2,662 participants and 7,473 screening studies at 21 international sites. Ultrasound studies were interpreted with blinding to mammography results. Simple cysts were noted, and features of all other Breast Imaging Reporting and Data System findings were recorded. Biopsy or mammography and ultrasound were used to determine malignancy rates at a minimum of 11 months of follow-up.

The researchers found that, based on the 2,172 participants (from 6,103 screening studies; median age at baseline, 54 years) ultimately included, there were 1,454 unique findings using ultrasound. There were 135 participants (6.2 percent) with 153 unique MB circumscribed breast masses, with no malignancies. In the 1,319 participants with 2,464 non-MB lesions (60.7 percent), there were 1,038 solitary circumscribed masses with a malignancy rate of 0.8 percent. For the 836 solitary circumscribed masses with at least two years of follow-up, the malignancy rate was 0.4 percent. More than 60 percent of the 135 women with MB circumscribed masses also had a solitary lesion, with two of these 82 women having cancer.

"We recommend diagnostic follow-up at one year for MB circumscribed benign-appearing masses identified at screening ultrasound, with resumption of screening thereafter if the mass is stable, but we recognize that larger studies need to be performed to document that this is a valid approach," the authors write.

Several authors disclosed financial ties to the imaging industry.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs